These findings provide clinical insight into how the bacterial-induced activation of the IL-33/ST2 pathway could contribute to asthma exacerbations, indicating that targeting this pathway may help in managing bacterial-triggered inflammation in asthmatic patients. This evidence concerns the gene IL33 and asthma.